Cargando…

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bicer, Fuat, Kure, Catrina, Ozluk, Anil A., El-Rayes, Bassel F., Akce, Mehmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670350/ https://www.ncbi.nlm.nih.gov/pubmed/37999131 http://dx.doi.org/10.3390/curroncol30110711

Ejemplares similares

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
por: Kang, Sandra, et al.
Publicado: (2022)

Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
por: Kang, Sandra Mirie, et al.
Publicado: (2022)

Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma
por: Zakka, Katerina, et al.
Publicado: (2019)

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
por: Sahin, Ibrahim Halil, et al.
Publicado: (2019)

The Potential of CAR T Cell Therapy in Pancreatic Cancer
por: Akce, Mehmet, et al.
Publicado: (2018)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

Emerging Therapies for Hepatocellular Carcinoma (HCC)
por: Chakraborty, Eesha, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma
por: Zakka, Katerina, et al.
Publicado: (2020)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Immunotherapy for advanced or recurrent hepatocellular carcinoma
por: Luo, Ying-Zhe, et al.
Publicado: (2023)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
por: Huang, Jingquan, et al.
Publicado: (2023)

Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study
por: Atallah, Rami P., et al.
Publicado: (2022)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023)

Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
por: Akce, Mehmet, et al.
Publicado: (2021)

Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
por: Xing, Mengtao, et al.
Publicado: (2021)

Association of emotional support with quality of life, mental health, and survival in older adults with gastrointestinal malignancies–Results from the CARE registry
por: Clausing, Daniel, et al.
Publicado: (2023)

The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis
por: Sartorius, Kurt, et al.
Publicado: (2019)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma
por: Lee, Yu Rim
Publicado: (2023)

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
por: Xie, Yingjun, et al.
Publicado: (2018)

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)
por: Dai, Liping, et al.
Publicado: (2013)

Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting
por: Bonferoni, Maria Cristina, et al.
Publicado: (2020)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device
por: Chu, Chia-Heng, et al.
Publicado: (2021)

Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis
por: Yilma, Mignote, et al.
Publicado: (2022)

The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC)
por: Kimura, Tomoki, et al.
Publicado: (2022)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ced0lpc19ppfpekh7cg95d3vs